Eric Fedyk

Company: Relay Therapeutics

Job title: Senior Vice President of Strategy

Seminars:

Closing Panel Discussion: Future Directions for BCMA-Directed Therapies 4:00 pm

Pricing/Cost Accessibility changes Is improved trial design needed? How will they be commercialized? What is the ultimate limit of BCMA as a target for myeloma? How will cell therapy infrastructure evolve & how will this effect current situation? Potential limitations to BCMA and how other targets (FcRb5/FcR115, NC28, CS1, SIRH5) could fit in the future…Read more

day: Day Two

The Potential of Repurposing BCMA-Targeted Biologics for Treating Autoimmune Diseases 4:30 pm

Understanding the multitude of unmet medical needs which could be addressed with a BCMA-targeted biologic Exploring how the pharmacology of antibodies can be similar in healthy volunteers, autoimmune and oncology patients Learning how antibodies which are effective in treating hematopoietic malignancies have also been re-purposed for the effective treatment of autoimmune diseasesRead more

day: Day One

Panel Discussion: How Do Cell-Based vs Antibody-Based Anti-BCMA Therapies Compare? 10:00 am

Navigating the current treatment landscape of multiple myeloma Bispecifics vs ADCs: Looking at PFS data? Can you compare cell-based vs antibody-based, based on combination rationale? Response, Efficacy, PFS, OS? Discussing BCMA’s potential and limitations; can we become curative? Gathering early clinical information to form robust translational outcomes Discussing the effect of extramedullary disease: should we…Read more

day: Day One